Therapeutic effects and quality of life in 37 glioma patients with postoperative intensity-modulated radiotherapy
10.3760/cma.j.issn.0254-5098.2010.06.023
- VernacularTitle:37例脑神经胶质瘤术后调强放疗的近期疗效及生存质量观察
- Author:
Danfang YAN
;
Senxiang YAN
;
Jinsong YANG
;
Xiaoli SUN
;
Zhongjie LU
- Publication Type:Journal Article
- Keywords:
Glioma;
Intensity-modulated radiotherapy;
Quality of life;
Cognitive function;
Memory disorder
- From:
Chinese Journal of Radiological Medicine and Protection
2010;30(6):721-724
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate treatment outcomes and quality of life (QOL) in glioma patients treated with postoperative intensity-modulated radiotherapy (IMRT), and to explore the possible clinical factors of affecting QOL. Methods From 2007 to 2009, 37 patients with low or high grade glioma were analyzed retrospectively. All patients were operated by tumor resection below microscopy. IMRT began at 2-4 week postoperstion with 2.0 Gy/fractior, 5 fractions/week and to shrink portal and to add dose to 50-60 Gy/25-30 fractions after 40-50 Gy. The gross tumor volume (GTV) was defined as preoperation T2WI MRI high sign area and postoperation tumor cavity for low grade glioma, and with preoperation T1WI MRI enhanced abnormity area and postoperation tumor cavity for high grade glioma. The clinical target volume ( CTV ) was defined as GTV with a margin of 1.5 cm for low grade glioma and a margin of 2.5 cm for high grade ghoma, the planning target volume (PTV) with CTV plus 0.4 cm margin for setup errors according to the European Organization for Research and Treatment of Cancer ( EORTC ).The treatment outcomes and QOL were assessed. Results The half-year and one-year survival rates for all the patients were 100% and 79.2%, respectively. The median progression-free survival time was 10 months. The main side-responses after postoperative IMRT were fatigue and mild memory decline or cognitive disabilities, which were radiation dose-dependent. Conclusions Postoperative IMRT is an effective and safe modality of therapy for glioma patients.
